REVIEW Naftopidil (Flivas) is an selective alpha1-adrenergic receptor antagonist or alpha blocker with a Ki of 58.3 nM. Naftopidil (Flivas) is an antihypertensive agent. Naftopidil (Flivas) binds specifically to alpha 1-adrenoceptors. The Ki values are 58.3 nM for naftopidi. In Japan, naftopidil is being used as a treatment for the bladder outlet obstruction in patients with benign prostatic hyperplasia.
REFERENCES
[1]
Himmel, Herbert M Naftopidil, a novel antihypertensive drug Cardiovascular Drug Reviews (1994), 12(1), 32-47.
[2]
Yuan JinQiu; Liu Yali; Yang ZuYao; Qin Xiwen; Yang KeHu; Mao Chen; The efficacy and safety of alpha-1 blockers for benign prostatic hyperplasia: an overview of 15 systematic reviews Current medical research and opinion (2013), 29(3), 279-87.
[3]
Sakai H, Igawa T, Onita T, Furukawa M, Hakariya T, Hayashi M, Matsuya F, Shida Y, Nishimura N, Yogi Y, Tsurusaki T, Takehara K, Nomata K, Shiraishi K, Shono T, Aoki D, Kanetake H, Efficacy of naftopidil in patients with overactive bladder associated with benign prostatic hyperplasia: prospective randomized controlled study to compare differences in efficacy between morning and evening medication. Hinyokika Kiyo. 2011 Jan;57(1):7-13.
[4]
Masumori, Naoya Naftopidil for the treatment of urinary symptoms in patients with benign prostatic hyperplasia Therapeutics and Clinical Risk Management (2011), 7, 227-238.
These chemical products are for research and development use only. They are not for diagnostic, therapeutic, cosmetic, or human and animal uses. They are not sold to individuals. Additional restrictions may apply.
New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information.
Add to Favorites 
Delete from Favorites 
